Skip to main content

Search

Reset all filters
1262 Result(s)
Sort by

Scleroderma Life Hacks

Scleroderma Life Hacks

Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
What are acute exacerbations in IPF?

What are acute exacerbations in IPF?

Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Technologies

Technologies

We are expanding our global network of technology partners Learn more about partnering with us.
survodutide top-line results MASH fibrosis

survodutide top-line results MASH fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Pet parasites are still here. What's the risk?

Pet parasites are still here. What's the risk?

What's the risk of pet parasites? They’re a growing challenge due to climate change. Check how to protect your dog and cat from fleas, ticks and more.
Annual Press Conference 2024

Annual Press Conference 2024

Boehringer Ingelheim presents the 2023 results and an outlook for 2024 at the Annual Press Conference on April 16, 2024.
PRRS vaccine discovery for swine

PRRS vaccine discovery for swine

PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Niha Agarwalla

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Brigitte Fuhr

Brigitte Fuhr

Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.